logo
Sign in

Biotherapeutics, Inc.

Blacksburg, VA · Biotech · Private

Small-molecule oral agonist therapeutic binding a novel immunological target for rheumatoid arthritis

Claim this profile

Follows are private to you and power your alerts

Updated · biotherapeuticsinc.com

Sector
Biotech
Headquarters
Blacksburg, VA
Total capital
$13.7M
Federal grants
$13.7M
29 awards · 2016–2025
Rank in peer group#20 of 514
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20162018202020222024FEDERAL ↑EQUITY ↓Cumulative $13.7M$1.1M$1.4M$643K$1.1M$564K$1.9M
20162018202020222024FEDERAL ↑EQUITY ↓Cumulative $13.7M$1.1M$1.4M$1.1M$1.9M

Latest events

  • Federal grantHealth and Human S · Phase II · A First-in-class Topical Immunoregulatory Therapeutic for Psoriasis$1.9M
  • Federal grantHealth and Human S · Phase I · Next-Gen Oral Therapeutics for Concomitant Clostridioides difficile Infection and IBD$314K
  • Federal grantHealth and Human S · Phase II · Novel Therapeutic for SLE$314K
  • Federal grantHealth and Human S · Phase I · Next-Gen Oral Therapeutics for Type 2 Diabetes$360K
  • Federal grantHealth and Human S · Phase I · The Next Wave of Asthma Therapeutics$348K
  • Federal grantHealth and Human S · Phase I · Development of Novel Immunoregulatory Therapeutics for Asthma$356K
  • Federal grantHealth and Human S · Phase I · Development of Novel Therapeutics for Asthma$289K
Show 22 earlier federal awards
  • Federal grantHealth and Human S · Phase I · Comparative Efficacy of Therapeutics for Clostridioides difficile Infection$300K
  • Federal grantHealth and Human S · Phase I · A First-in-class Topical Immunoregulatory Therapeutic for Psoriasis$295K
  • Federal grantHealth and Human S · Phase I · Novel first-in-class Therapeutics for Rheumatoid Arthritis$296K
  • Federal grantHealth and Human S · Phase I · Development of Novel Topical Therapeutics for Psoriasis$296K
  • Federal grantHealth and Human S · Phase II · Novel Immunoregulatory Therapeutics for Systemic Lupus Erythematosus$564K
  • Federal grantHealth and Human S · Phase I · Immunoregulatory Therapeutics for Ulcerative Colitis$356K
  • Federal grantHealth and Human S · Phase II · Novel Immunoregulatory Therapeutics for Systemic Lupus Erythematosus$1.1M
  • Federal grantHealth and Human S · Phase I · Targeting the Immunometabolic Hub Nlrx1 as a Novel Therapeutic for Asthma$362K
  • Federal grantHealth and Human S · Phase II · Effects of Abscisic Acid on Insulin Sensitivity$420K
  • Federal grantHealth and Human S · Phase I · The First LANCL2-based therapeutic for influenza$300K
  • Federal grantHealth and Human S · Phase II · Validation of Immunometabolic NLRX1 Therapeutics for IBD$643K
  • Federal grantHealth and Human S · Phase I · Novel Immunoregulatory Therapeutics for Systemic Lupus Erythematosus$300K
  • Federal grantHealth and Human S · Phase I · The First Pomegranate Seed Oil-Containing Medical Food for Gut and Immune Health$295K
  • Federal grantHealth and Human S · Phase I · Developing Novel NLRX1-Based Immuno-Oncology Therapeutics$231K
  • Federal grantHealth and Human S · Phase II · Effects of Abscisic Acid on Insulin Sensitivity$1.4M
  • Federal grantHealth and Human S · Phase II · Validation of Immunometabolic NLRX1 Therapeutics for IBD$1.1M
  • Federal grantHealth and Human S · Phase I · Novel Immunoregulatory Drugs for Type 1 Diabetes$231K
  • Federal grantHealth and Human S · Phase I · Development of Antibiotic-Free Clostridium difficile Therapeutics$300K
  • Federal grantHealth and Human S · Phase II · Effects of Abscisic Acid on Insulin Sensitivity$282K
  • Federal grantHealth and Human S · Phase I · Immunometabolic NLRX1 Therapeutics for IBD$233K
  • Federal grantHealth and Human S · Phase I · BT-11: A First-in-class Oral Therapeutic for Inflammatory Bowel Disease$300K
  • Federal grantHealth and Human S · Phase I · The First Abscisic Acid-Containing Medical Food for Glycemic Control$250K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

  • Federal grants#20 · top 4%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .